Efficacy and acceptability of risedronate 5 mg daily compared with 35 mg once weekly for the treatment of postmenopausal osteoporosis

Basit Öğe Kaydı
dc.authorid0000-0002-0517-7310en_US
dc.contributor.authorKaralok, Hakan
dc.contributor.authorTüfekçi, E. C.
dc.contributor.authorBatur, Osman
dc.date.accessioned2024-07-12T21:03:00Z
dc.date.available2024-07-12T21:03:00Z
dc.date.issued2006en_US
dc.departmentFakülteler, Tıp Fakültesien_US
dc.description.abstractObjective Risedronate is a bisphosphonate used in the treatment of osteoporosis. It has a strong effect in inhibiting osteoclast activity. The primary objective of this study was to evaluate the effectiveness and adverse events of two different forms of risedronate (5 mg and 35 mg) using a rapid biochemical marker for comparison of C-terminal telopeptide (CTx) type I collagen cross-links. Methods The study was designed at Bakırkoy Dr. Sadi Konuk Education & Research Hospital, between January and June 2004. A total of 123 postmenopausal osteoporotic women were randomly assigned in blocks of three to one of the following groups: control, risedronate 5 mg/day and risedronate 35 mg once a week. Results Of the 123 women enrolled, 103 (83.7%) completed the study. Adverse events were experienced by 53.6% in the control group, 56% in the risedronate 5 mg/day group and 53.6% in the group receiving risedronate 35 mg once per week. The most common adverse events were gastrointestinal (21.9% of subjects in group 1, 29.2% of subjects in group 2, 24.3% of subjects in group 3). The women in groups receiving risedronate either 5 mg/day and 35 mg once per week had similarly decreased levels of CTx but the control group was not as effective. Conclusion The results support the hypothesis that risedronate 35 mg given once per week has the same therapeutic efficacy and safety as a daily 5 mg regimen. Taking the medicine once a week is likely to be easier and more satisfactory than the daily regimen. However, patients taking a once-a-week regimen may forget to take it due to the 7-day break without medicine.en_US
dc.identifier.citationIlter, E., Karalok, H., Tufekci, E. C. ve Batur, O. (2006). Efficacy and acceptability of risedronate 5 mg daily compared with 35 mg once weekly for the treatment of postmenopausal osteoporosis. Climacteric., Taylor and Francis Online. 9(2), s. 129–134.en_US
dc.identifier.doi10.1080/13697130600652180
dc.identifier.endpage134en_US
dc.identifier.issn1369-7137
dc.identifier.issn1473-0804
dc.identifier.issue2en_US
dc.identifier.pmid16698659en_US
dc.identifier.scopus2-s2.0-33646476988en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage129en_US
dc.identifier.urihttps://www.tandfonline.com/doi/abs/10.1080/13697130600652180?journalCode=icmt20
dc.identifier.urihttps://doi.prg/10.1080/13697130600652180
dc.identifier.urihttps://hdl.handle.net/20.500.12415/3609
dc.identifier.volume9en_US
dc.identifier.wosWOS:000237935100007en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorİlter, Erdin
dc.language.isoenen_US
dc.publisherTaylor and Francis Onlineen_US
dc.relation.ispartofClimactericen_US
dc.relation.publicationcategoryUluslararası Hakemli Dergide Makale - Kurum Öğretim Elemanıen_US
dc.rightsCC0 1.0 Universal*
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.rights.urihttp://creativecommons.org/publicdomain/zero/1.0/*
dc.snmzKY00518
dc.subjectRisedronateen_US
dc.subjectDaily or weekly regimenen_US
dc.subjectBone resorptionen_US
dc.subjectC-terminal telopeptide type I collagenen_US
dc.titleEfficacy and acceptability of risedronate 5 mg daily compared with 35 mg once weekly for the treatment of postmenopausal osteoporosisen_US
dc.typeArticle
dspace.entity.typePublication

Dosyalar

Koleksiyon

Tıp Fakültesi Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu